Singapore's Health Sciences Authority (HSA) revised Appendix 17 of its PRISM submission guidance for therapeutic product registration, with the revised appendix and the matching Appendices 2A, 3A, 13A and 14A taking effect from September 30, 2026. The revised Appendix 17 defines a packaging configuration, which describes how a product is supplied, and sets out how to determine whether a product is submitted as an individual registration or as multiple packaging configurations under a single product registration.
Singapore therapeutic product registrants filing via PRISM, local applicants for chemical and biological therapeutic product registration, and companies supplying a therapeutic product in Singapore in more than one pack presentation must apply the revised Appendix 17 packaging-configuration rule on every registration filed from September 30, 2026, using the updated Appendices 2A, 3A, 13A and 14A, or a PRISM submission that groups or splits pack presentations against the revised definition will not match the filing standard HSA applies.
What changed in Appendix 17
The Therapeutic Products Branch (TPB) revised Appendix 17 after reviewing feedback from its consultation with industry stakeholders. The appendix defines a packaging configuration, how a product is supplied, and guides the decisive question at filing: whether a pack presentation is one individual registration, or several packaging configurations grouped under a single product registration.
HSA updated Appendices 2A, 3A, 13A and 14A to reflect the revised definition, so the submission checklists a registrant works through in PRISM all apply the same test. The changes took effect from September 30, 2026, per HSA's regulatory update, which points registrants to the updated guidance documents for the detailed text.
Who must apply the revised rule
The revision binds every party that files a therapeutic product registration through PRISM, or supplies a registered therapeutic product in Singapore. The exposed actors, by market exposure:
- Singapore therapeutic product registrants filing via PRISM, who must align each new submission with the revised Appendix 17 test.
- Local applicants for chemical therapeutic product registration, whose submissions must apply the updated appendices.
- Local applicants for biological therapeutic product registration, whose submissions must apply the updated appendices.
- Companies supplying a therapeutic product in Singapore in more than one pack presentation, for whom the choice between individual registration and packaging configuration is most consequential.
What to file differently from September 30, 2026
From September 30, 2026, every therapeutic product registration filed through PRISM must apply the revised Appendix 17 definition. The required action is to determine, per the revised test, whether each pack presentation is its own individual registration or a packaging configuration under a single product registration, and to complete the matching submission checklists in Appendices 2A, 3A, 13A and 14A in their updated form.
Registrants should re-read the revised appendix before their next submission, map each pack presentation against the packaging-configuration definition, and confirm the registration strategy before filing in PRISM. A submission built on the old packaging-configuration logic will not match the standard in force from September 30, 2026.
What happens to a non-compliant PRISM submission
HSA names no fine in the announcement. The operative consequence is procedural: a PRISM submission that groups or splits pack presentations against the revised Appendix 17 definition will not match the filing standard HSA applies from September 30, 2026, so a registrant filing under the old logic risks rejection or rework at submission rather than a monetary penalty.
The announcement also flags a second item. HSA is reviewing the Minor Variation (MIV) Checklist and will publish the revised checklist for industry consultation from mid-November to mid-December 2026, with consultation and feedback arrangements shared alongside it. That consultation is not an action yet: registrants should review the draft when published and respond within the window.
| HSA update | Status | Date | Action for registrants |
|---|---|---|---|
| Appendix 17 revision (with Appendices 2A, 3A, 13A, 14A) | In force | From September 30, 2026 | Apply the revised packaging-configuration test on every PRISM filing |
| Minor Variation (MIV) Checklist revision | Consultation planned | Mid-November to mid-December 2026 | No action yet; review the draft when published and respond in the consultation |
What to do next
- Check whether your Singapore therapeutic product portfolio includes more than one pack presentation, where the revised Appendix 17 test bites hardest.
- Read the revised Appendix 17 and the updated Appendices 2A, 3A, 13A and 14A on the HSA guidance documents page before your next PRISM submission.
- Map each pack presentation to individual registration or packaging configuration under a single registration, and document the rationale per the revised test.
- Brief your regulatory affairs team on the September 30, 2026 effective date, and flag the mid-November to mid-December 2026 MIV checklist consultation for response.
Continuous, per-jurisdiction monitoring surfaces this kind of guidance revision the moment HSA publishes it, so a registrant's next filing follows the standard in force; Obsidian tracks the Singapore therapeutic product register and the PRISM guidance set so compliance teams do not discover a changed appendix at submission.
